Brainomix, a leading provider of AI-powered imaging solutions for stroke and lung fibrosis, has announced the appointment of Khush F. Mehta as Chair of its Board of Directors. The move comes at a pivotal time as the company accelerates its global growth and expands commercial activities in key markets, particularly the United States.
Mehta succeeds Professor Jacqueline (Jackie) Hunter CBE, who led the board over the past five years and oversaw the company’s transformation from an emerging innovator to an established player in healthcare AI.
“Khush brings an outstanding track record of global leadership in medical technology and AI,” said Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix. “His strategic insights and operational experience—especially in scaling businesses across the US, Europe, and Asia—will be instrumental as we continue to grow our presence in stroke and lung care.”
Based in the US, Mehta will advise on Brainomix’s internationalization strategy, drawing on his previous roles as Chairman of Arterys (acquired by Tempus AI in 2022) and Chief Strategy Officer at Siemens Healthcare. His academic credentials include an MBA from Yale and a Master’s in Commerce and Financial Management from Sydenham College, Mumbai.
Strategic expansion backed by recent investment and FDA approval
Mehta’s appointment follows Brainomix’s recent £14M ($18M) Series C funding round, aimed at scaling its Brainomix 360 stroke platform across the US and other global markets. The company also recently received FDA clearance for a novel, patented feature in its stroke platform, reinforcing its leadership in real-world AI imaging applications.
“Brainomix has built one of the most clinically validated AI platforms in stroke care,” said Khush F. Mehta, newly appointed Chair. “I’m honored to support the company in this exciting next phase as it scales into new geographies and therapeutic areas. With strong foundations in Europe and a growing US presence, Brainomix is uniquely positioned to lead the future of AI in medical imaging.”
A leadership legacy and a vision for the future
Outgoing Chair Prof. Jackie Hunter reflected on her tenure, during which Brainomix doubled in size, secured widespread clinical adoption of its stroke AI platform, and launched its e-Lung platform. Under her guidance, the company expanded internationally and forged strategic partnerships with leading pharma companies.
“It has been a privilege to serve as Chair during such a dynamic growth phase,” said Prof. Hunter. “The team has built something truly impactful, and I’m excited to see Brainomix continue to deliver value for patients worldwide.”
The transition also marks the retirement of Andrew Barker, the company’s Founding Chair and former Board Director. His early leadership helped shape Brainomix’s journey from a University of Oxford spin-out to a scale-up with global potential.
